SHR-A1811 + SHR-1701 + capecitabine

SHR-A1811 + SHR-1701 + capecitabine is an investigational combination therapy consisting of three agents: - **SHR-A1811**: a third-generation antibody-drug conjugate (ADC) targeting HER2, showing promising antitumor activity and acceptable tolerability in HER2-positive cancers. - **SHR-1701**: also known as retlirafusp alfa, a bifunctional fusion protein that targets both programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β) pathways, acting simultaneously as an immune checkpoint inhibitor and TGF-β trap. SHR-1701 is under investigation for various advanced solid tumors, including gastric cancer, esophageal cancer, colorectal cancer, and others. - **Capecitabine**: an oral prodrug of 5-fluorouracil (5-FU), a well-established antimetabolite chemotherapeutic agent commonly used in gastrointestinal and breast cancers. Clinical research is examining the safety and efficacy of this combination in HER2-expressing advanced solid tumors, notably gastric and gastroesophageal junction cancers, among others, with ongoing or planned trials. Each component targets different but complementary mechanisms of tumor growth and immune evasion.

Other names

retlirafusp alfa + SHR-A1811 + capecitabine